Search Results 771-780 of 15929 for SC

  1. Publications - Samy M. Riad, M.D. - Mayo Clinic

    Epub 2025 Jan 30. View PubMed; Kukla A, Lester SC, Iqbal A, Razonable RR, Issa N, Riad S, Fox JC, Prieto M, Kudva YC. Pancreas irradiation for treatment ...

  2. Safety Study of SEA-CD40 in Cancer Patients - Mayo Clinic

    Solid tumor monotherapy (both IV and SC administration): No further standard therapy is available for the patient's advanced solid tumor at the time of ...

  3. Publications - Matthew T. Heller, M.D. - Mayo Clinic

    ... SC, Expert Panel on Urologic Imaging . ACR Appropriateness Criteria((R)) Hematospermia. J Am Coll Radiol. 2017 May; 14 (5S):S154-S159 View PubMed; Taffel MT ...

  4. A Study Comparing 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR to Treat Patients with Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours - Mayo Clinic

    It is acceptable to have patients temporarily switched to Octreotide s.c. (up to six weeks) in order to obtain an OctreoScan®, provided they return to the same ...

  5. Publications - LaPrincess C. Brewer, M.D., M.P.H. - Mayo Clinic

    ... SC, Hines AL, Ibrahim NE, Jackson EA, Joynt Maddox KE, Makaryus AN, Pina IL, Rodriguez-Monserrate CP, Roger VL, Thorpe FF, Williams KA Sr, Writing Committee ...

  6. Clinical Trial Enzyme Application Targeting Venous Leg Ulcers

    Sponsor Protocol Number: SC-VLU-001. About this study. To assess the safety and tolerability of multiple ascending doses of Aurase Wound Gel when administered ...

  7. Publications - Christoph Wald, M.D., Ph.D. - Mayo Clinic

    Epub 2021 Jan 13. View PubMed; Tellis R, Starobinets O, Prokle M, Raghavan UN, Hall C, Chugh T, Koker E, Chaduvula SC, Wald C, Flacke S. Identifying Areas ...

  8. Publications - Prashant Kapoor, M.D. - Mayo Clinic

    ... SC, Breen WG, Kyle RA, Gertz MA, Rajkumar SV, Gonsalves WI. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone ...

  9. Oncology (Medical) - Clinical trials

    [MUSIC PLAYING]. Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first.

  10. A Study to Evaluate the Effectiveness and Safety of RalinEpag for Improving Treatment Outcomes in PAH Patients - Mayo Clinic

    Hemoglobin concentration <9 g/dL at Screening. 12. Subjects treated with an IV or SC prostacyclin pathway agent (eg, epoprostenol, treprostinil, or iloprost) ...